Healthcare -
Biotechnology - NASDAQ - US
$ 18.85
2.56 %
$ 606 M
Market Cap
-6.66
P/E
1. INTRINSIC VALUE
Balance Sheet
Dianthus Therapeutics, Inc.
| Current Assets | 281 M |
| Cash & Short-Term Investments | 275 M |
| Receivables | 807 K |
| Other Current Assets | 4.86 M |
| Non-Current Assets | 93.1 M |
| Long-Term Investments | 81.7 M |
| PP&E | 1.75 M |
| Other Non-Current Assets | 9.63 M |
| Current Liabilities | 18.5 M |
| Accounts Payable | 4.58 M |
| Short-Term Debt | 320 K |
| Other Current Liabilities | 13.6 M |
| Non-Current Liabilities | 3.08 M |
| Long-Term Debt | 2.34 M |
| Other Non-Current Liabilities | 737 K |
EFFICIENCY
Earnings Waterfall
Dianthus Therapeutics, Inc.
| Revenue | 6.24 M |
| Cost Of Revenue | 0 |
| Gross Profit | 6.24 M |
| Operating Expenses | 108 M |
| Operating Income | -102 M |
| Other Expenses | -16.9 M |
| Net Income | -85 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Dianthus Therapeutics, Inc.
| Net Income | -85 M |
| Depreciation & Amortization | 412 K |
| Capital Expenditures | -105 K |
| Stock-Based Compensation | 12.9 M |
| Change in Working Capital | -351 K |
| Others | -14.7 M |
| Free Cash Flow | -78.3 M |
Wall Street Analysts Price Targets
Dianthus Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for DNTH of $52 , with forecasts ranging from
a
low of
$52 to a high of $52 .
DNTH Lowest Price Target
Wall Street Target
52 USD
175.86%
DNTH Average Price Target
Wall Street Target
52 USD
175.86%
DNTH Highest Price Target
Wall Street Target
52 USD
175.86%
4. DIVIDEND
ANALYSIS
DNTH does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Dianthus Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors.
globenewswire.com
- 1 month ago
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D.
globenewswire.com
- 1 month ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.54 per share a year ago.
zacks.com
- 1 month ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2025, and provided an update on recent business achievements.
globenewswire.com
- 1 month ago
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis (gMG).
globenewswire.com
- 2 months ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events.
globenewswire.com
- 2 months ago
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
zacks.com
- 3 months ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago.
zacks.com
- 3 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided an update on recent business achievements.
globenewswire.com
- 3 months ago
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion
globenewswire.com
- 4 months ago
Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:
globenewswire.com
- 4 months ago
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:
globenewswire.com
- 5 months ago
8. Profile
Summary
Dianthus Therapeutics, Inc. DNTH
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 606 M
Dividend Yield
0.00%
Description
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Contact
7 Times Square, New York City, NY, 10036
https://dianthustx.com
IPO
Date
June 21, 2018
Employees
78
Officers
Mr. Edward G. Carr
Chief Accounting Officer
Mr. Adam M. Veness Esq.
Senior Vice President, General Counsel & Secretary
Mr. Scott Nogi M.B.A.
Head of Business Operations
Mr. Ryan Savitz
Chief Financial Officer & Chief Business Officer
Ms. Kristina Maximenko
Chief People Officer
Ms. Rashieda Gluck
Head of Clinical Development Operations
Mr. Judson Taylor
Senior Vice President & Head of Technical Operations
Mr. Marino Garcia M.B.A.
President, Chief Executive Officer & Director
Mr. Simrat Randhawa M.B.A., M.D.
Chief Medical Officer
Ms. Jennifer Davis Ruff
Vice President and Head of Investor Relations & Corporate Affairs.